Views: 50 Author: Unibest Industrial Publish Time: 2025-01-06 Origin: Site
Report generated for the week of 2025-01-06 by Unibest Digital Center. Current analysis scope only include the US FDA.
This week, there are 8 drugs in the patent and exclusivity list. They are:
- AZURITY PHARMACEUTICALS INC's EDARBI, containing active ingredient AZILSARTAN KAMEDOXOMIL
- ABBVIE INC's TRILIPIX, containing active ingredient CHOLINE FENOFIBRATE
- AZURITY PHARMACEUTICALS INC's EDARBYCLOR, containing active ingredient AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE
- TEVA NEUROSCIENCE INC's UZEDY, containing active ingredient RISPERIDONE
- TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE
- BLUEPRINT MEDICINES CORP's AYVAKIT, containing active ingredient AVAPRITINIB
- BOEHRINGER INGELHEIM's GILOTRIF, containing active ingredient AFATINIB DIMALEATE
- CEPHALON INC's TRISENOX, containing active ingredient ARSENIC TRIOXIDE
From AZURITY PHARMACEUTICALS INC; for treating hypertension
Approved in Feb 25, 2011, used as Reference Listed Drug
There are 2 future patent(s) for this application. The earliest expires on 2025-05-22, and the latest expires on 2028-03-26.
Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date | Patent Title |
---|---|---|---|---|
7572920 | U-3 | TREATMENT OF HYPERTENSION | 2025-01-07 | Benzimidazole derivative and use as a II receptor antagon |
From AZURITY PHARMACEUTICALS INC; for treating hypertension
Approved in Dec 20, 2011, used as Reference Listed Drug
There are 4 future patent(s) for this application. The earliest expires on 2025-05-22, and the latest expires on 2031-07-01.
Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date | Patent Title |
---|---|---|---|---|
7572920 | U-3 | TREATMENT OF HYPERTENSION | 2025-01-07 | Benzimidazole derivative and use as a II receptor antagon |
From ABBVIE INC; for treating high levels of fat or cholesterol in the blood
Approved in Dec 15, 2008, used as Reference Listed Drug and Reference Standard
There are no future patents for this application.
Patent No | Patent Expiration Date | Patent Title |
---|---|---|
7259186 | 2025-01-07 | Salts of fenofibric acid and pharmaceutical formulations thereof |
Approved in Dec 15, 2008, used as Reference Listed Drug
There are no future patents for this application.
Patent No | Patent Expiration Date | Patent Title |
---|---|---|
7259186 | 2025-01-07 | Salts of fenofibric acid and pharmaceutical formulations thereof |
From TEVA NEUROSCIENCE INC; for treating a number of mental health disorders including schizophrenia, bipolar mania, psychosis, or as an adjunct in severe depression
All approved in Apr 28, 2023, used as Reference Listed Drug
There are 4 future patent(s) for this application. The earliest expires on 2027-11-12, and the latest expires on 2040-09-11.
Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date | Patent Title |
---|---|---|---|---|
10736965 | 2025-01-12 | Risperidone biodegradable implant | ||
9439905 | U-543 | TREATMENT OF SCHIZOPHRENIA | 2025-01-12 | Risperidone-containing implants and methods of use thereof |
9895447 | 2025-01-12 | Drug-containing PLA implants and methods of use thereof | ||
9925268 | 2025-01-12 | Drug-containing implants and methods of use thereof | ||
9717799 | 2025-01-12 | Drug-containing implants and methods of use thereof | ||
8802127 | 2025-01-12 | Risperidone-containing PLA:PGA implants and methods of use thereof |
From BOEHRINGER INGELHEIM; for treating locally advanced or metastatic NSCLC with non-resistant EGFR mutations or resistance to platinum-based chemotherapy
Approved in Jul 12, 2013, used as Reference Listed Drug
There are 3 future exclusivity(ies) for this drug product. The earliest expires on 2025-04-07, and the latest expires on 2025-10-07.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2025-01-12 | FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST |
Approved in Jul 12, 2013, used as Reference Listed Drug and Reference Standard
There are 3 future exclusivity(ies) for this drug product. The earliest expires on 2025-04-07, and the latest expires on 2025-10-07.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2025-01-12 | FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST |
From CEPHALON INC; for treating refractory or relapsed acute promyelocytic leukemia in patients with prior retinoid and anthracycline chemotherapy
Approved in Oct 13, 2017, used as Reference Listed Drug and Reference Standard
There are no future exclusivities for this application.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2025-01-12 | ARSENIC TRIOXIDE FOR USE IN COMBINATION WITH TRETINOIN FOR TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION |
From BLUEPRINT MEDICINES CORP; for treating multidrug resistant gastrointestinal tumors
Approved in Jan 9, 2020, used as Reference Listed Drug
There are 4 future exclusivity(ies) for this drug product. The earliest expires on 2026-05-22, and the latest expires on 2030-05-22.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2025-01-09 | NEW CHEMICAL ENTITY |
Approved in Jun 16, 2021, used as Reference Listed Drug
There are 4 future exclusivity(ies) for this drug product. The earliest expires on 2026-05-22, and the latest expires on 2030-05-22.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2025-01-09 | NEW CHEMICAL ENTITY |
Approved in Jan 9, 2020, used as Reference Listed Drug and Reference Standard
There are 4 future exclusivity(ies) for this drug product. The earliest expires on 2026-05-22, and the latest expires on 2030-05-22.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2025-01-09 | NEW CHEMICAL ENTITY |
From TEVA PHARMACEUTICAL INDUSTRIES LTD; for preventing asthma attacks and flare-ups or worsening of COPD
Approved in Jan 27, 2017, used as Reference Listed Drug
There are no future exclusivities for this application.
Exclusivity Date | Exclusivity Use Definition |
---|---|
2025-01-09 | PEDIATRIC EXCLUSIVITY |